Translate
Urticaria and Angioedema Management
Urticaria and Angioedema Management identifies triggers, optimises antihistamine therapy, and uses biologic treatment when standard therapy fails -- providing sustained relief from the debilitating daily itch, wheals, and swellings of chronic urticaria.
Overview
Chronic spontaneous urticaria causes daily or near-daily symptoms for months to years with profound quality of life impact. EAACI guidelines recommend second-generation antihistamines at up to four times standard dose as first-line treatment, escalated to omalizumab when maximum-dose antihistamines fail. Complete symptom control (UAS7 of 0) is the treatment target.
Types of Urticaria
- Chronic Spontaneous Urticaria (no identifiable external trigger -- most common)
- Cold Contact Urticaria (potentially life-threatening in cold water)
- Symptomatic Dermographism (whealing from mechanical stroking)
- Solar Urticaria (wheals from UV light exposure)
- Pressure Urticaria (delayed whealing from sustained pressure)
- Hereditary Angioedema (C1 inhibitor deficiency -- life-threatening)
- Drug-Induced Urticaria (NSAIDs, ACE inhibitors, antibiotics)
- Food-Induced Urticaria (acute -- IgE-mediated food allergy)
Treatment Pathway
- Step 1 (standard dose second-generation antihistamine daily)
- Step 2 (up to 4 times standard dose antihistamine)
- Step 3 (add omalizumab 300 mg monthly)
- Step 4 (add ciclosporin for omalizumab-refractory cases)
- UAS7 of 0 is the complete control target
- Treatment response assessed at 4 weeks after each change
- Step-down after 12 months of sustained control
- Spontaneous remission occurs in 50% within 5 years
Urticaria Symptoms Requiring Specialist Assessment
- Daily or near-daily urticaria persisting for more than 6 weeks
- Failure to achieve control with maximum dose antihistamine
- Angioedema of the face, lips, tongue, or throat
- Angioedema unresponsive to antihistamines and corticosteroids
- Recurrent angioedema without wheals requiring C1 inhibitor assay
- Urticaria with systemic features suggesting urticarial vasculitis
- Occupational or social disability from urticaria
- Urticaria in a patient with suspected mastocytosis
Key Benefits
Discover the advantages of choosing our urticaria and angioedema management services.
Omalizumab achieves complete response in 35 to 40% of CSU patients at 3 months
Maximum dose antihistamine achieves control in 40 to 50% of CSU patients before biologic escalation
Identifying and avoiding triggers reduces exacerbation frequency and severity
Early HAE diagnosis prevents unnecessary dangerous administration of antihistamines and steroids
Step-down from omalizumab is successful in 30 to 50% of patients achieving long-term remission
Clinical Features
The technology, techniques and clinical approach behind our urticaria and angioedema management.
UAS7 measured at every appointment -- the primary objective treatment response outcome measure
Maximum-dose antihistamine therapy completed before biologic escalation
Angioedema without wheals triggers C4/C1 inhibitor testing to exclude HAE which requires entirely different treatment
Omalizumab step-down trials conducted at 12 months of complete control
Cold and inducible urticaria threshold testing guides precise trigger avoidance advice
Preparation Instructions
Take antihistamines daily rather than as-needed -- consistent dosing provides better control for chronic urticaria. Avoid known personal triggers where practical. Carry an emergency epinephrine auto-injector if you have had severe throat angioedema. Attend omalizumab injection appointments on schedule. Contact your dermatologist urgently for throat tightening, difficulty breathing, or voice change from angioedema.
The Procedure
Step-by-step guide to what you can expect during your urticaria and angioedema management procedure.
UAS7 Score and DLQI Review
The weekly Urticaria Activity Score (UAS7) combining daily wheal count and itch severity provides the objective disease control measure. Both scores guide treatment step-up or step-down decisions at every appointment.
Antihistamine Optimisation
Second-generation non-sedating antihistamines are prescribed at up to four times the licensed standard dose -- the evidence-based ceiling dose before escalating to biologic therapy.
Trigger Identification and Avoidance
Known triggers (NSAIDs ACE inhibitors emotional stress heat exercise cold) are identified and avoided where possible. Inducible urticaria trigger threshold testing documents disease severity.
Omalizumab Initiation
When maximum dose antihistamine fails omalizumab 300mg subcutaneously monthly is initiated. Response assessment at 3 to 6 months determines continuation.
Hereditary Angioedema Assessment
Angioedema without wheals triggers C4 and C1 inhibitor level and function testing to exclude hereditary angioedema. HAE requires specific treatment and not antihistamines or corticosteroids.
Step-Down After Sustained Control
After 12 months of complete control on omalizumab step-down trials are conducted. Most patients maintain remission during step-down with 30 to 50% remaining in remission after stopping.
What to Expect
Your dermatologist reviews UAS7 scores, photographs, and antihistamine response. Blood tests exclude thyroid disease and systemic mastocytosis. Antihistamine therapy is optimised and omalizumab is initiated when EAACI criteria are met. For hereditary angioedema, C1 inhibitor levels are checked and appropriate prophylactic treatment prescribed.
Frequently Asked Questions
Common questions about urticaria and angioedema management.
Related Services
Explore other services in our Dermatology department.
Psoriasis Management
Eczema and Atopic Dermatitis
Skin Lesion Assessment and Biopsy
Ready to Get Started?
Schedule your consultation today and take the first step towards better health.
